Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632579 · ClinicalTrials.gov registry record · Phase 1
A Single Dose Study of LY3023703 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01632579 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 30 participants.
The verdict
NCT01632579, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a phase I study of LY3023703 in healthy participants. The purposes of this study are to look at safety, how well the study drug is tolerated, how much of the study drug gets into the blood stream, and how long it takes the body to get rid of it when given to humans. Information about any side effects that may occur will also be collected. Participants will remain in the study for approximately 3 months. This study is for research purposes only and is not intended to treat any medical condition.
Interventions
- DRUG Placebo
- DRUG Celecoxib
- DRUG LY3023703
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-06 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01632579
The ClinicalTrials.gov registry entry for NCT01632579 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01632579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01632579 about?
NCT01632579 is a clinical study titled "A Single Dose Study of LY3023703 in Healthy Participants". This is a phase I study of LY3023703 in healthy participants. The purposes of this study are to look at safety, how well the study drug is tolerated, how much of the study drug gets into the blood stream, and how long it takes the body to get rid of it when given to humans. Information about any sid...
What is the current status of trial NCT01632579?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-06. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01632579?
The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG), LY3023703 (DRUG).
Who is sponsoring clinical trial NCT01632579?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.